QuidelOrtho (QDEL) is expanding its QUICKVUE portfolio with the QUICKVUE Influenza + SARS Test, a CLIA-waived, 510(k)-cleared rapid, easy-to-use immunoassay designed for professional use in physician ...
QuidelOrtho Corporation recently expanded its QUICKVUE portfolio with the launch of the QUICKVUE Influenza + SARS Test, a rapid, CLIA-waived immunoassay for professional use that delivers simultaneous ...
Designed for symptomatic individuals within six days of symptom onset, the QuickVue COVID-19 test is cleared for use in individuals aged 14 or older when self-testing, and in those aged two and older ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback